Results 41 to 50 of about 18,733 (258)
FEBS Letters, EarlyView.Although too much iron in the brain promotes neurodegeneration, iron ion chelators have had mixed effects in clinical trials. This review explains why; some chelators do not render the iron redox‐inactive (e.g., L1) whereas others do (e.g., desferrioxamine).
Barry Halliwell
wiley +1 more source
The health economic potential of harnessing placebos in treatment of ADHD
European Psychiatry, 2021 Introduction Placebo research investigated the underlying mechanisms of placebo effects, but they are rarely used to optimize treatments. Ethical and legal concerns have been raised, but research demonstrated that placebo mechanisms can be used without
J. Hamberger +3 more
doaj +1 more source
Molecular Oncology, EarlyView.Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang +12 more
wiley +1 more source
Investigación utilizando placebos
Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica, 2018 Este caso debemos analizarlo partiendo de dos principios éticos fundamentales: no hacer daño y beneficencia. El principio de no hacer daño tiene una gran cercanía con el principio hipocrático primun non noscere, que es el principio más básico de una ...
José María Maya
doaj +3 more sources
Frontiers in Medicine, 2021 Introduction: Open-label placebos have been proposed as way of using long recognized analgesic placebo effects in an ethical manner. Recent evidence shows efficacy of open-label placebos for clinical conditions, but there is need for more research on ...
Dilan Sezer +10 more
doaj +1 more source
Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer
Molecular Oncology, EarlyView.Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas +16 more
wiley +1 more source
BMC Medicine, 2023 Background Overtreatment poses a challenge to healthcare systems due to harmful consequences of avoidable side-effects and costs. This study presents the first account for examining the feasibility of placebo use for reducing overtreatment in primary ...
E. M. Krockow +4 more
doaj +1 more source
Study of the placebo effect with a placebo test
Comprehensive Psychiatry, 1968 Summary This paper briefly reviewed several methodological problems in studies of the placebo effect. The importance of finding appropriate measures of placebo effect was emphasized. This led to an attempt to develop a more valid and reliable test of placebo reactivity.
A K, Shapiro +2 more
openaire +2 more sources
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
Are treatments more effective than placebos? A systematic review and meta-analysis.
PLoS ONE, 2013 BackgroundPlacebos are widely used in clinical practice in spite of ethical restrictions. Whether such use is justified depends in part on the relative benefit of placebos compared to 'active' treatments. A direct test for differences between placebo and
Jeremy Howick +8 more
doaj +1 more source